UK M&A deals of the month: September 2026

September brought a clear acceleration in UK public M&A, although capital remained concentrated around a relatively small number of high-conviction transactions. Nine companies entered an offer period during the month, up from four in August, while overseas acquirers represented 75% of disclosed bidders. Companies worth less than £500m still accounted for 63% of businesses in an offer period, but the proportion valued above £1bn rose to 26%.

Those figures sit within a market where transaction values have recovered faster than volumes. Office for National Statistics data published on 1 September showed the number of completed UK-involved acquisitions falling from 407 in the first quarter to 353 in the second, while the value of inward acquisitions increased from £15.7bn to £25.4bn. Domestic transactions were worth £4.2bn, with outward acquisitions totalling £2.7bn.

PwC’s mid-year figures showed a similar concentration. Announced UK M&A value reached £124.2bn in the first half of 2026, 107% higher than a year earlier, despite deal numbers falling 13% to 1,301. Almost two-thirds of the total value sat within the ten largest transactions.

August’s deal activity had already shown buyers paying substantial premiums where an acquisition secured infrastructure, technology, customer relationships, or market access that would take years to reproduce. September extended that pattern into specialist engineering, healthcare, communications, enterprise IT, and energy, while also bringing more visible competition between bidders.

Veritas secures Bodycote at £1.85bn enterprise value

Bodycote’s lengthy takeover process reached agreement on 1 September when US private equity group Veritas Capital secured the board’s recommendation for a 940p-per-share offer value.

The terms comprise 932.8p in cash and allow shareholders to retain a 7.2p interim dividend. Including that dividend, the transaction values Bodycote’s fully diluted equity at approximately £1.65bn and implies an enterprise value of around £1.85bn. The offer value stands 37.5% above the three-month volume-weighted average share price before takeover speculation emerged in May.

Competition developed steadily through the process. Bodycote initially received an unsolicited approach from Apollo before separate proposals emerged from Veritas and CVC, with both latter bidders subsequently improving their terms several times. CVC reached 915p per share and Veritas 914p before Veritas returned on 31 August with the 940p proposal that secured the board’s backing.

Behind the price sits a highly specialised industrial business. Bodycote operates approximately 130 facilities across 22 countries, providing heat treatment and other thermal-processing services to aerospace, defence, automotive, energy, and industrial customers. Many of those activities depend on technical know-how, customer approvals, specialist equipment, and long-standing relationships that cannot be recreated quickly.

Veritas already has significant exposure to aerospace, defence, and engineered industrial technology, giving it a clear strategic rationale for owning the business. Bodycote, meanwhile, had been pursuing its own programme to improve margins, reduce costs, and increase exposure to higher-growth markets, leaving the board to weigh the certainty of a cash offer against the returns available from continuing independently.

Several credible bidders ultimately pushed the valuation higher. Rather than accepting the first workable proposal, Bodycote’s process allowed competitive tension to develop around a business whose capabilities and global footprint would require substantial time and capital to replicate.

Toscafund-led consortium agrees £1.03bn Spire takeover

Private healthcare supplied another substantial public-to-private transaction when Spire Healthcare agreed a recommended acquisition by a consortium involving Toscafund, Three Hills, and Ares Management.

The 250p-per-share cash offer values Spire’s equity at approximately £1.03bn and implies an enterprise value of £2.31bn. It represents a 66.2% premium to Spire’s 150.4p closing price immediately before the possible offer was announced in May. Eligible shareholders can alternatively elect to retain economic exposure through rollover securities in the new ownership structure.

Agreement followed an approximately eight-month strategic review during which Spire and its advisers contacted more than 60 potential financial and strategic acquirers. The board also examined alternatives including continued independent ownership, asset disposals, and potential monetisation of the group’s freehold estate before concluding that 250p represented the highest formal proposal received.

The scale of the premium needs to be read alongside that process rather than in isolation. Spire operates a capital-intensive healthcare estate whose value depends on sustained investment in hospitals, equipment, clinical capacity, and workforce. Its enterprise value is also substantially higher than its quoted equity value once borrowings and lease liabilities are taken into account.

The new owners will inherit both a sizeable physical platform and the investment demands attached to it. Public shareholders receive the certainty of an immediate cash exit, while those eligible for the rollover alternative can retain exposure to future performance under a different ownership structure with different liquidity and governance characteristics.

Private capital has increasingly been drawn to businesses where returns depend on investment over longer periods than public markets always reward comfortably. Spire fits that profile, with an established national position, significant tangible assets, and a continuing requirement to fund capacity and operational improvement over several years.

Epiris takes Gamma private in £1.02bn deal

Gamma Communications became another sizeable UK-listed target on 1 September, when private equity group Epiris agreed a recommended 1,120p-per-share cash acquisition.

The transaction values Gamma’s fully diluted equity at approximately £1.02bn and implies an enterprise value of around £1.08bn. The acquisition price represents a 53% premium to the company’s closing share price immediately before the offer period began in April.

Gamma had attracted interest from several parties, with its board considering proposals for the entire company as well as approaches for individual parts of the group. Selected bidders were given access to management and due diligence information, while proposals judged insufficient on value or execution certainty were rejected before Epiris emerged with the recommended offer.

Its investment case combines an established customer base with the need for further spending. Gamma provides business communications technology across the UK and Europe through proprietary products, third-party cloud platforms, its telecommunications network, and a large channel partner base. Epiris plans to increase investment in product development, commercial execution, and AI adoption as it seeks stronger organic growth in the UK business.

That programme will now be pursued away from the public market. Gamma brings recurring customer relationships, cash generation, distribution, and established positions in the UK and Germany, but converting those advantages into faster growth will require continued investment and management execution.

The transaction places that execution risk with Epiris in exchange for control of the eventual upside. Shareholders receive cash at a substantial premium, while the new owner gains a longer investment horizon for developing the business.

Softcat pays £785m for immediate US scale

September was not solely a month of overseas buyers taking UK companies private. Softcat moved in the opposite direction on 17 September, agreeing its largest acquisition to date with a $1.05bn enterprise-value purchase of US technology solutions provider GDT, equivalent to approximately £785m.

The acquisition gives the FTSE 250 company an established North American operation alongside additional capability in networking, data centres, AI infrastructure, and cyber security. GDT also brings an enterprise and upper mid-market customer base, extensive vendor relationships, and a Bengaluru operation supporting engineering and service delivery.

Rather than funding the transaction entirely from its existing balance sheet, Softcat plans to combine £100m of cash with £550m of new debt facilities and approximately £350m raised through an equity issue. Management expects the acquisition to produce high single-digit to low double-digit underlying earnings-per-share accretion during its first full financial year.

Building an equivalent US business organically would mean acquiring customers, recruiting technical teams, establishing vendor relationships, developing delivery infrastructure, and gaining credibility in a market where incumbency carries weight. GDT delivers those components together and gives Softcat an immediate platform from which to serve customers operating across the Atlantic.

Financing the deal through cash, borrowing, and fresh equity also creates a clear return threshold. International expansion, cross-selling, and the enlarged service proposition will need to generate returns above the cost of the capital committed.

Unlike the month’s take-private transactions, the progress of that strategy will remain visible in the public market. Softcat shareholders are backing management to turn a substantial one-off deployment of capital into durable international earnings growth.

Genel raises Capricorn offer to $436m

Capricorn Energy produced September’s clearest bidding contest after DNO attempted to displace Genel Energy’s previously agreed acquisition.

DNO announced an offer for Capricorn on 1 September and improved it on 17 September. Genel responded on 25 September with an increased recommended proposal valuing Capricorn’s fully diluted equity at approximately $436m, or £330m at the exchange rate used in the offer documentation.

The revised terms deliver approximately $5.74 per share, comprising $4.75 in cash and a permitted special dividend of $0.99. That represented a 10% premium to DNO’s revised acquisition value and 63% above Capricorn’s closing share price before the offer period began in March.

Capricorn’s board consequently withdrew its recommendation of the DNO offer and returned its support to Genel, while investors representing approximately 39.1% of issued share capital provided revised irrevocable undertakings.

Competition centred on Capricorn’s Egyptian portfolio and the diversification it would give Genel. The process became particularly fluid because Genel’s original transaction had already received overwhelming shareholder approval in August before DNO intervened with a competing proposal the following month.

By late September, shareholders had benefited from the resulting contest, while both bidders had been forced to demonstrate more than their willingness to pay. Financing certainty, regulatory progress, shareholder commitments, transaction conditions, and the probability of completion all formed part of the board’s assessment as the competing proposals moved higher.

What September’s deals say about UK M&A

Across the five transactions, September reinforced the concentration already visible in the first half of the year. Overall deal numbers remain below previous levels, but more capital is being committed where buyers believe an acquisition provides access to capabilities, assets, or markets that are difficult to secure by other means.

The pickup in public offer activity widened that exposure. Nine companies entered an offer period during September, more than twice August’s four, and overseas acquirers accounted for three-quarters of disclosed bidders. Smaller businesses still represented most targets numerically, even as several £1bn-plus transactions accounted for a disproportionate share of the month’s value and attention.

Large premiums appeared repeatedly, although each emerged from a different process. Spire’s 66.2% premium followed an extensive strategic review involving dozens of potential buyers. Gamma’s 53% premium came after discussions with several interested parties. Bodycote secured progressively better proposals as rival bidders remained engaged, while Capricorn’s valuation increased as Genel and DNO competed directly for control.

Those buyers were generally paying for established positions rather than speculative growth. Bodycote brings specialist industrial processes and customer approvals; Gamma contributes communications technology, recurring customers, and distribution; Spire owns a national healthcare platform; Capricorn provides producing energy assets; and GDT gives Softcat immediate US scale in technology infrastructure markets being expanded by AI-related investment.

Private ownership is absorbing part of the investment risk. Veritas and Epiris are taking responsibility for funding the next phases of Bodycote and Gamma away from public markets, while the Spire consortium is committing to a hospital group whose performance depends on continued capital expenditure and operating improvement.

Softcat provides the counterweight to those transactions. Its acquisition of GDT shows a listed UK company using M&A to accelerate its own expansion rather than becoming the target of somebody else’s strategy. The £785m enterprise value buys an established market position, technical expertise, customer access, and delivery capacity in one transaction, albeit with a significant financing commitment attached.

September closed with more businesses in play and more evidence of competitive bidding, but little sign of capital becoming indiscriminate. Buyers are still concentrating their largest commitments around assets with defensible positions, while target boards are being forced to compare standalone plans against increasingly well-funded approaches from private equity, strategic buyers, and overseas investors.

September’s transactions leave UK M&A heading into the final quarter with greater activity but continued selectivity. Overseas and private capital remain prominent, while the strongest offers are clustering around businesses with specialised capabilities, established positions, or assets that accelerate the buyer’s route to scale. Where several credible bidders want the same advantage, quoted valuations can move quickly.